This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Triple releasing agent: Difference between revisions
>BronzeManul Rewrote intro to 'dewikify' it, correct various errors, correct several links that originally led to various non-existent pages, and add a relevant citation. |
>Tracer |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
'''Triple releasing agent (TRA)''', also known as a ('''serotonin-norepinephrine-dopamine releasing agent (SNDRA)'''), is a type of psychoactive substance that induces the release of four major central nervous system [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], [[epinephrine]], and [[dopamine]], in the body and/or brain. Triple releasing agents are known to typically produce [[Euphoria|euphoriant]], [[entactogen]], and [[stimulant]] effects, and are almost exclusively encountered in the context of [[recreational drug use]]. | '''Triple releasing agent (TRA)''', also known as a ('''serotonin-norepinephrine-dopamine releasing agent (SNDRA)'''), is a type of psychoactive substance that induces the release of four major central nervous system [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], [[epinephrine]], and [[dopamine]], in the body and/or brain. Triple releasing agents are known to typically produce [[Euphoria|euphoriant]], [[entactogen]], and [[stimulant]] effects, and are almost exclusively encountered in the context of [[recreational drug use]]. | ||
A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drugs]], with [[cocaine]] being a prominent example. | A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also typically produce an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Unlike triple releasing agents, triple reuptake inhibitors have been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an antidepressant,{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} Other triple reuptake inhibitors see widespread use as [[recreational drug use|recreational drugs]], with [[cocaine]] being a prominent example. | ||
==Neurotoxicity== | ==Neurotoxicity== | ||
| Line 40: | Line 40: | ||
* [[Agonist]] | * [[Agonist]] | ||
* [[Antagonist]] | * [[Antagonist]] | ||
==External links== | |||
*[[wikipedia:Serotonin-norepinephrine-dopamine releasing agent|Serotonin-norepinephrine-dopamine releasing agent (Wikipedia)]] | |||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Approval]] | |||